TearLab Corporation develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab® Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab® Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Press ReleasesLatest NewsFDA Grants TearLab® Osmolarity System CLIA Waiver Categorization
TearLab® Published in AAO Preferred Practice Patterns
TearLab Enters Into Cooperative Marketing Agreementwith Abbott Medical Optics' Canadian Subsidiary
|
The Dry Eye Review |